natgillin/translations-raw huggingface dataset:
Plastična škatla s 5 x 1 odmerkom cepiva in 5 x 1 vialo (stekleno) z vehiklom Plastična škatla s 25 x 1 odmerek cepiva in 25 x 1 vialo (stekleno) z vehiklom Kartonska škatla z 10 x 50 odmerki cepiva
Plastic box with 5 x 1 dose of vaccine including 5 x 1 ml solvent vials (glass) Plastic box with 25 x 1 dose of vaccine including 25 x 1 ml solvent vials (glass) Cardboard box with 10 x 50 doses of vaccine
Plastična škatla s 5 x vialo z 1 odmerkom cepiva in 5 x vialo z 1 ml vehikla
Plastic box with 5 x 1 dose vial of vaccine and 5 x 1 ml vial of solvent.
Plastična škatla s 5 x vialo z 1 odmerkom cepiva in 5 x vialo z 1 ml vehikla.
Plastic box with 5 x 1 dose vial of vaccine and 5 x 1 ml vial of solvent.
PLATO включва пациенти, които на изходно ниво имат застойна сърдечна недостатъчност, ХОББ или астма; тези пациенти и пациентите в старческа възраст е по-вероятно да съобщават диспнея.
PLATO included patients with baseline congestive heart failure, COPD, or asthma; these patients, and the elderly, were more likely to report dyspnoea.
Plavix 300 mg филмирани таблетки клопидогрел
Plavix 300 mg film-coated tablets clopidogrel
Plavix 300 mg филмирани таблетки клопидогрел (clopidogrel)
Plavix 300-mg film-coated tablets clopidogrel
Plavix 300 mg филмирани таблетки са продълговати, розови, с гравирано числото “300“ на едната страна и числото “1332” на другата страна.
Plavix 300-mg film-coated tablets are oblong, pink, engraved on one side with the number ‘300’ and on the other side with the number ‘1332’.
Plavix 75 mg филмирани таблетки клопидогрел
Plavix 75 mg film-coated tablets clopidogrel
Plavix 75 mg филмирани таблетки клопидогрел (сlopidogrel)
Plavix 75 mg film-coated tablets clopidogrel
Plavix 75 mg филмирани таблетки са кръгли, двойно-изпъкнали, розови, с гравирано числото “75“ на едната страна и числото “1171” на другата страна.
Plavix 75-mg film-coated tablets are round, biconvex, pink, engraved on one side with the number ‘75’ and on the other side with the number ‘1171’.
Plavix Ви е предписан за предотвратяване на образуването на кръвни съсиреци и намаляване на риска от тези сериозни инциденти, защото:
You have been prescribed Plavix to help prevent blood clots and reduce the risk of these severe events because:
Plavix е малко вероятно да засегне способността Ви за шофиране или работа с машини.
Plavix is unlikely to affect your ability to drive or to use machines.
Plavix може да се приема със или без храна.
Plavix may be taken with or without food.
Plavix с храна и напитки
Plavix with food and drink
Plavix се доставя в картонени кутии съдържащи:
Plavix is supplied in cardboard cartons containing:
Plavix се предлага в картонени кутии съдържащи 4 x 1, 10 x 1, 30 x 1 и 100 x 1 таблетки в алуминиеви перфорирани еднодозови блистери.
Plavix is supplied in cardboard cartons containing 4x1, 10x1, 30x1 and 100x1 tablets in all aluminium perforated unit-dose blisters.
Plazemska razpolovna doba izločanja fenofibratne kisline traja približno 20 ur.
The plasma elimination half-life of fenofibric acid is approximately 20 hours.
Plazemski očistek pri bolnikih z jetrno okvaro (serumski bilirubin med 1.5 in 10 mg/dl) se je v primerjavi s kontrolno skupino znižal na približno 67 %.
10 mg/dl) decreased to about 67 % when compared with a control group of patients.
Plazemski očistek pri bolnikih z ledvično okvaro (očistek kreatinina 41-60 ml/min) se je v primerjavi s kontrolno skupino zmanjšal na približno 67 %.
Plasma clearance in patients with renal impairment (creatinine clearance 41-60 ml/min.) decreased to about 67 % compared with control patients.
plazmatické koncentrace
concentrations.
Plazmatické koncentrace nezměněného orlistatu byly 8 hodin po perorálním podání 360 mg orlistatu neměřitelné ( 5 ng/ml).
Plasma concentrations of intact orlistat were non-measurable (<5 ng/ml) 8 hours following oral administration of orlistat 360 mg.
PLD 40 mg/m2 като i.v. инфузия със скорост 1 mg/min само в ден 1 на всеки 4 седмици.
PLD 40 mg/m2 as a 1 mg/min IV infusion on Day 1 only every 4 weeks.
Plegridy 125 µg инжекция
Plegridy 125 mcg injection
Plegridy 125 микрограма инжекционен разтвор в предварително напълнена писалка
Plegridy 125 micrograms solution for injection in pre-filled pen.
Plegridy 125 микрограма инжекционен разтвор в предварително напълнена писалка пегинтерферон бета-1a
Plegridy 125 micrograms solution for injection in pre-filled pen peginterferon beta-1a
Plegridy 125 микрограма инжекционен разтвор в предварително напълнена спринцовка
Plegridy 125 micrograms solution for injection in pre-filled syringe.
Plegridy 125 микрограма на всеки 2 седмици
Plegridy 125 micrograms every 2 weeks
Plegridy 125 микрограма на всеки 4 седмици
Plegridy 125 micrograms every 4 weeks
Plegridy 63 µg инжекция Plegridy 94 µg инжекция
Plegridy 63 mcg injection Plegridy 94 mcg injection
Plegridy 63 микрограма инжекционен разтвор в предварително напълнена писалка Plegridy 94 микрограма инжекционен разтвор в предварително напълнена писалка
Plegridy 63 micrograms solution for injection in pre-filled pen Plegridy 94 micrograms solution for injection in pre-filled pen
Plegridy 63 микрограма инжекционен разтвор в предварително напълнена писалка Plegridy 94 микрограма инжекционен разтвор в предварително напълнена писалка Plegridy 125 микрограма инжекционен разтвор в предварително напълнена писалка Пегинтерферон бета-1a (Peginterferon beta-1a)
Plegridy 63 micrograms solution for injection in pre-filled pen Plegridy 94 micrograms solution for injection in pre-filled pen Plegridy 125 micrograms solution for injection in pre-filled pen Peginterferon beta-1a
Plegridy 63 микрограма инжекционен разтвор в предварително напълнена спринцовка Plegridy 94 микрограма инжекционен разтвор в предварително напълнена спринцовка
Plegridy 63 micrograms solution for injection in pre-filled syringe Plegridy 94 micrograms solution for injection in pre-filled syringe
Plegridy 63 микрограма инжекционен разтвор в предварително напълнена спринцовка Plegridy 94 микрограма инжекционен разтвор в предварително напълнена спринцовка Plegridy 125 микрограма инжекционен разтвор в предварително напълнена спринцовка Пегинтерферон бета-1a (Peginterferon beta-1a)
Plegridy 63 micrograms solution for injection in pre-filled syringe Plegridy 94 micrograms solution for injection in pre-filled syringe Plegridy 125 micrograms solution for injection in pre-filled syringe Peginterferon beta-1a
Plegridy е лекарство, съдържащо активното вещество пегинтерферон бета-1a (peginterferon beta- 1a).
Plegridy is a medicine that contains the active substance peginterferon beta-1a.
Plegridy е писалка за еднократна употреба.
Plegridy is a single-use pen.
Plegridy изглежда действа, като не позволява на имунната система на организма да уврежда главния и гръбначния Ви мозък.
Plegridy seems to work by stopping the body’s immune system from damaging your brain and spinal cord.
Plegridy може да предизвика гадене (вижте точка 4 „Възможни нежелани реакции”).
Plegridy may make you feel sick (see section 4 “Possible side effects”).
Plegridy може да се съхранява извън хладилник при стайна темепратура (до 25°C) в продължение на максимум 30 дни, но трябва да се съхранява на тъмно.
Plegridy can be kept outside a fridge at room temperature (up to 25°C) for up to 30 days but it must be kept away from light.
Plegridy не трябва да бъде използван при пациенти, които понастоящем страдат от тежка депресия или имат мисли за самоубийство.
Plegridy must not be used in patients who are currently suffering from severe depression or have thoughts of suicide.
Plegridy представлява бистър и безцветен инжекционен разтвор в предварително напълнена писалка.
Plegridy is a clear and colourless solution for injection in a pre-filled pen.
Plegridy представлява бистър и безцветен инжекционен разтвор в предварително напълнена спринцовка.
Plegridy is a clear and colourless solution for injection in a pre-filled syringe.
Plegridy се отпуска по лекарско предписание и лечението трябва да бъде започнато под контрола на лекар, който има опит в лечението на МС.
Plegridy can only be obtained with a prescription and treatment should be started under the supervision of a doctor experienced in treating MS.
Plegridy се предлага под формата на инжекционен разтвор в предварително напълнени писалки или предварително напълнени спринцовки, съдържащи 63, 94 или 125 микрограма пегинтерферон бета-1a.
Plegridy is available as a solution for injection in pre-filled pens or pre-filled syringes that contain 63, 94 or 125 micrograms peginterferon beta-1a.
Plegridy се свързва с интерфероновия рецептор тип І на повърхността на клетките и предизвиква каскада от вътреклетъчни събития, водещи до регулация на експресията на интерферон-чувствителния ген.
Plegridy binds to the type I interferon receptor on the surface of cells and elicits a cascade of intracellular events leading to the regulation of interferon-responsive gene expression.
Plegridy също така намалява значимо риска от пристъп с 39% (р=0,0003), риска от устойчива прогресия на инвалидността, потвърден след 12 седмици, с 38% (р=0,0383), а след 24 седмици (post hoc анализ) с 54% (р=0,0069), броя на новите или наново разширяващите се Т2 лезии с 67% (р<0,0001), броя на Gd-усилените лезии с 86% (р<0,0001) и броя на новите хипоинтензни Т1 лезии, в сравнение с плацебо, с 53% (р<0,0001).
Plegridy also significantly reduced the risk of relapse by 39% (p=0.0003), the risk of sustained disability progression confirmed at 12 weeks by 38% (p=0.0383) and at 24 weeks (post-hoc analysis) by 54% (p=0.0069), the number of new or newly enlarging T2 lesions by 67% (p<0.0001), the number of Gd-enhancing lesions by 86% (p<0.0001) and the number of new T1 hypointense lesions compared to placebo by 53% (p<0.0001).
Plenadren 20 mg с изменено освобождаване хидрокортизон
Plenadren 20 mg modified-release tablets hydrocortisone
Plenadren 20 mg таблетки с изменено освобождаване
Plenadren 20 mg modified-release tablets
Plenadren 20 mg таблетки с изменено освобождаване EU/1/11/715/002
Plenadren 20 mg modified-release tablets EU/1/11/715/002
Plenadren 20 mg таблетки с изменено освобождаване хидрокортизон
Plenadren 20 mg modified-release tablets hydrocortisone
Plenadren 20 mg: Всяка таблетка с изменено освобождаване съдържа 20 mg хидрокортизон.
Plenadren 20 mg: Each modified-release tablet contains 20 mg of hydrocortisone.
Plenadren 5 mg с изменено освобождаване хидрокортизон
Plenadren 5 mg modified-release tablets hydrocortisone
Plenadren 5 mg таблетки с изменено освобождаване
Plenadren 5 mg modified-release tablets
Plenadren 5 mg таблетки с изменено освобождаване EU/1/11/715/001
Plenadren 5 mg modified-release tablets EU/1/11/715/001
Plenadren 5 mg таблетки с изменено освобождаване Plenadren 20 mg таблетки с изменено освобождаване
Plenadren 5 mg modified-release tablets Plenadren 20 mg modified-release tablets
Plenadren 5 mg таблетки с изменено освобождаване хидрокортизон
Plenadren 5 mg modified-release tablets hydrocortisone
Plenadren 5 mg: Всяка таблетка с изменено освобождаване съдържа 5 mg хидрокортизон.
Plenadren 5 mg: Each modified-release tablet contains 5 mg of hydrocortisone.
Plenadren е лекарствен продукт, съдържащ активното вещество хидрокортизон (hydrocortisone).
Plenadren is a medicine that contains the active substance hydrocortisone.
Plenadren може да се използва по време на бременност.
Plenadren can be used during pregnancy.
Plenadren може да се използва по време на кърмене.
Plenadren can be used during breast-feeding.
Plenadren не трябва да се прилага при хора, които може да са свръхчувствителни (алергични) към хидрокортизон или някоя от останалите съставки.
Plenadren must not be used in people who are hypersensitive (allergic) to hydrocortisone or any of the other ingredients.
Plenadren оказва минимално влияние върху способността за шофиране и работа с машини.
Plenadren has minor influence on the ability to drive and use machines.
Plenadren с храни и напитки
Plenadren with food and drink
Plenadren се използва за лечение на надбъбречна недостатъчност при възрастни.
Plenadren is used to treat adrenal insufficiency in adults.
Plenadren, приеман веднъж дневно, е сравнен с конвенционална хидрокортизонова терапия, прилагана три пъти дневно.
Plenadren, given once per day, was compared with conventional hydrocortisone treatment, which is given three times per day.
PlGF може да бъде синергист на VEGF-A в тези процеси, а освен това е известно, че спомага за левкоцитната инфилтрация и съдовото възпаление.
PlGF can synergize with VEGF- A in these processes, and is also known to promote leucocyte infiltration and vascular inflammation.
plin za inhaliranje
Inhalation gas
plin za inhaliranje
Inhalation gas.
Pliva Croatia Ltd, Prilaz baruna Filipovića 25, 10000 Zagreb, Хърватска
PLIVA Hrvatska d.o.o. (PLIVA Croatia Ltd.), Prilaz baruna Filipovića 25, 10000 Zagreb, Croatia
Pliva Hrvatska d.o.o Tel: + 385 1 37 20 000
Pliva Hrvatska d.o.o Tel: + 385 1 327 20 000
Pliva Hrvatska d.o.o Tel: + 385 1 37 20 000
Teva Pharmaceuticals Ireland Tel: +353 (0) 51 321 740
Pliva Hrvatska d.o.o.
Teva Gyógyszergyár Zrt.
Pliva Hrvatska d.o.o.
Teva Santé
Pliva Hrvatska d.o.o.
Teva Ελλάς Α.Ε. Ελλάδα
Pliva Ljubljana d.o.o.
Teva UK Limited
Pljučna hipertenzija, povezana s srčnim kirurškim posegom
Pulmonary hypertension associated with heart surgery
Pljučne in nosne poti: izcedek iz nosu, motnje glasu, zamašitev nosu, faringealni eritem, seneni nahod
Lung and nasal passages: runny nose, voice disorder, nasal clogging, pharyngeal erythema, hay fever
Pljučne in nosne poti: kratka sapa, kašelj
Lung and nasal passages: shortness of breath, cough
pljučnica
pneumonia
Plodnost
Fertility:
Plodnost, nosečnost in dojenje
Fertility, pregnancy and lactation
Plodnost, nosečnost in dojenje‌‌
Fertility, Pregnancy and lactation
Plodnost, nosečnost in dojenje‌‌
Fertility, Pregnancy and lactation‌‌
Plodnost,nosečnost in dojenje
Fertility, pregnancy and lactation
Plodnosti pri ženskah niso raziskovali.
Female fertility was not investigated.
Plodnosť
Fertility
Plynatost spojená s výtokem Nucení na stolici
Fatty oily stool Oily evacuation Flatulence
Plötslig svullnad av läppar, ansikte, hals eller tunga; svåra hudutslag och problem att svälja eller andas.
Sudden swelling of your lips, face, throat or tongue; a severe rash; and, swallowing or breathing problems.
plötsligt uppkommande kraftiga hudutslag, hudblåsor eller flagande hud, möjligen tillsammans med hög feber eller ledsmärtor (dessa kan vara tecken på svårare tillstånd såsom toxisk epidermal nekrolys, Stevens-Johnsons syndrom, erythema multiforme eller ett tillstånd känt som DRESS, läkemedelsreaktion med eosinofili och systemiska symtom) svullnad under huden, speciellt läpparna och runt ögonen
udden onset of a severe rash or blistering or peeling skin, possibly accompanied by a high fever or joint pain (these may be signs of more serious medical conditions such as toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme or a condition known as DRESS, Drug Reaction with Eosinophilia and Systemic Symptoms) swelling under the skin, particularly lips and around the eyes
Po 24 tednih zdravljenja je bil ustekinumab po kriterijih aktivnosti bolezni bistveno učinkovitejši kot placebo.
Treatment with ustekinumab resulted in significant improvements in the measures of disease activity compared to placebo at week 24.
Po 44 tednih so bili deleži bolnikov, ki so vzdrževali klinično remisijo in odziv na zdravljenje, statistično značilno večji v skupinah, ki sta prejemali ustekinumab, v primerjavi s placebom (glejte preglednico 4).
Significantly higher proportions of patients maintained clinical remission and response in the ustekinumab treated groups compared to the placebo group at week 44 (see Table 4).
Po 6 ciklih se zdravljenje s cisplatinom prekine, zdravilo Teysuno pa se ne ukine.
Cisplatin should be discontinued after 6 cycles without withdrawal of Teysuno.
PO Box 552
Postbus 552
Po dobu vysazování přípravku Intuniv se doporučuje postupné snižování dávky (tzv. tapering), aby se minimalizovaly tyto potenciální příznaky z vysazení.
Tapering Intuniv dosing during withdrawal is recommended to minimise these potential withdrawal effects.
Po enem letu (52. teden) je 89% bolnikov, ki so bili ponovno naključno uvrščeni v skupino za vzdrževalno zdravljenje, pokazalo odziv PASI 75, v primerjavi s 63% bolnikov, ki so bili ponovno naključno uvrščeni v skupino za prejemanje placeba (prenehanje zdravljenja) (p < 0,001).
At 1 year (week 52), 89% of patients re-randomised to maintenance treatment were PASI 75 responders compared with 63% of patients re-randomised to placebo (treatment withdrawal) (p < 0.001).
Po enem peroralnem odmerku 75 mg je razpolovni čas klopidogrela približno 6 ur.
After a single oral dose of 75 mg, clopidogrel has a half-life of approximately 6 hours.
Po enkratnem in večkratnih peroralnih odmerkih 75 mg na dan se klopidogrel hitro absorbira.
After single and repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed.
Po enkratnem intravenskem bolusu danem zdravim preiskovancem je očistek palonosetrona 173 ± 29 ml/min in ledvični očistek 53 ± 29 ml/min.
After a single intravenous bolus administration in healthy subjects the total body clearance of palonosetron was 173 ± 73 ml/min and renal clearance was 53 ± ml/min.
Po enkratnem odmerku so opazili statistično značilno zmanjšanje vrednosti Cmax za 5-FU in gimeracil v skupini s hudo jetrno okvaro v primerjavi z vrednostjo v normalni skupini, po večkratnem odmerjanju pa te razlike niso opazili.
After single dose administration, there was a statistically significant decrease in 5-FU and gimeracil Cmax for the severe hepatic impairment group relative to that of the normal group, but this difference was not observed after multiple dose administration.
Po enkratnem odmerku zdravila Teysuno so vrednosti T1/2 znašale od 6,7 do 11,3 ure za tegafur, od 3,1 do 4,1 ure za gimeracil in od 1,8 do 9,5 ure za oteracil.
Following a single dose of Teysuno, T1/2 values ranged from 6.7 to 11.3 hours for tegafur, from 3.1 to 4.1 hours for gimeracil, and from 1.8 to 9.5 hours for oteracil.
Po enkratni subkutani injekciji je bila absolutna biološka uporabnost ustekinumaba pri bolnikih s psoriazo ocenjena na 57,2%.
The absolute bioavailability of ustekinumab following a single subcutaneous administration was estimated to be 57.2% in patients with psoriasis.
Po enojnem intravenskem odmerku 10 mikrogramov/kg [14C] - palonosetrona, se 80 % odmerka v 144 urah izloči v urinu, kjer je 40 % danega odmerka palonosetrona aktivna nespremenjena substanca.
After a single intravenous dose of 10 micrograms/kg [14C]-palonosetron, approximately 80 % of the dose was recovered within 144 hours in the urine with palonosetron representing approximately 40 % of the administered dose, as unchanged active substance.
Po injiciranju:
After the injection:
Po intravenski uporabi se 47 % odmerka izloči prek ledvic, 53 % pa biliarno in z biotransformacijo.
After intravenous administration, 47% of the dose is eliminated by the renal excretion and 53% by biliary excretion and biotransformation.
Po nenadni prekinitvi zdravljenja z vdihavanjem dušikovega oksida so opisali hitre povratne (»rebound«) reakcije kot sta povečana pljučna vazokonstrikcija in hipoksija, ki so povzročile kardiovaskularni kolaps.
Rapid rebound reactions such as intensified pulmonary vasoconstriction and hypoxia after sudden withdrawal of inhaled nitric oxide therapy has been described, precipitating cardiovascular collapse.
Po odmerni shemi 300 mg/75 mg se je antiagregacijski odziv pri slabih metabolizatorjih zmanjšal: povprečno IPA (5 µM ADP) je bilo 24 % (24 ur) in 37 % (5. dan) v primerjavi z 39 % (24 ur) in 58 % (5. dni) pri dobrih metabolizatorjih ter 37 % (24 ur) in 60 % (5. dan) pri srednjih metabolizatorjih.
After the 300 mg/75 mg dose regimen, antiplatelet responses were decreased in the poor metabolisers with mean IPA (5 μM ADP) of 24% (24 hours) and 37% (Day 5) as compared to IPA of 39% (24 hours) and 58% (Day 5) in the extensive metabolisers and 37% (24 hours) and 60% (Day 5) in the intermediate metabolisers.
Po odstranitvi pokrovčka z igle takoj injicirajte zdravilo.
Inject the dose promptly after removing the needle cover.
Po odstranitvi pokrovčka z igle, takoj injicirajte zdravilo.
Inject the dose promptly after removing the needle cover.
Po okužbi z miksoma virusom se pri nekaterih cepljenih živalih lahko pojavi nekaj zelo majhnih oteklin, posebno na neporaščenih delih telesa, ki se hitro spremenijo v kraste.
After infection with virulent myxoma virus some vaccinated animals may develop a few very small swellings, especially on hairless places of the body, which quickly form scabs.
Po okužbi z miksomatozo se pri nekaterih cepljenih živalih lahko pojavi nekaj zelo majhnih oteklin, posebno na neporaščenih delih telesa, ki se hitro spremenijo v kraste.
After infection with virulent myxoma virus some vaccinated animals may develop a few very small swellings, especially on hairless places of the body, which quickly form scabs.
Po peroralnem odmerku s 14C-označenega klopidogrela pri človeku, se ga je približno 50 % izločilo z urinom in približno 46 % z blatom v 120 urnem intervalu po odmerjanju.
Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing.
Po peroralni uporabi se je oteracil z visokimi koncentracijami porazdelil v normalno tkivo gastrointestinalnega trakta, medtem ko je bilo v krvnem in tumorskem tkivu opaziti znatno nižje koncentracije pri študijah na živalih.
After oral administration, oteracil was distributed at high concentrations in normal gastrointestinal tract tissues while considerably lower concentrations were seen in blood and tumour tissue in animal studies.
Po perorálním podání [14C]kobicistatu představoval 99 % cirkulující radioaktivity v plazmě nezměněný kobicistat.
Following oral administration of [14C]cobicistat, 99% of circulating radioactivity in plasma was unchanged cobicistat.
Po perorálním podání [14C]kobicistatu se 86% dávky vyloučilo stolicí a 8,2% dávky se vyloučilo močí.
Following oral administration of [14C]cobicistat, 86% and 8.2% of the dose were recovered in faeces and urine, respectively.
Po podání jednorázové 400 mg dávky 14C-atazanaviru se ve stolici a v moči zjistilo 79 % a 13 % celkové radioaktivity.
Following a single 400 mg dose of [14C]atazanavir, 79% and 13% of the total radioactivity was recovered in the faeces and urine, respectively.
Po podání perorální dávky klopidogrelu značeného 14C se u člověka přibližně 50 % látky vyloučí močí a přibližně 46 % stolicí během 120 hodin po podání.
Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing.
Po potrebi je dodana še druga možnost (jakost svetlobe 200 mW/cm) za prilagoditev laserjev s skupno zmogljivostjo, ki ne presega 2,5 W.
A second option (light intensity of 200 mW/cm) has also been included where necessary to accommodate lasers with a total capacity that does not exceed 2.5 W.
Po potrebi je treba spremeniti odmerke zaradi sprožitvenih neželenih učinkov (glejte poglavje 4.2).
Dose modifications should be applied for the precipitating adverse reaction as necessary (see section 4.2).
Po potrebi moramo skrbno spremljati očistek kreatinina.
If necessary, creatinine clearance should be closely monitored.
Po približno 90-tih dneh po injekciji PhotoBarra je treba preskusiti občutljivost kože na svetlobo, kot sledi:
About 90 days after the PhotoBarr injection, you should test the photosensitivity of your skin as follows:
Po pripravi je PhotoBar temno rdeča do rdečkastorjava motna raztopina.
After reconstitution, PhotoBarr is a dark red to reddish brown, opaque solution.
Po pripravi je PhotoBarr temno rdeča do rdečkastorjava motna raztopina.
After reconstitution, PhotoBarr is a dark red to reddish brown, opaque solution.
Po pripravi je treba PhotoBarr zaščititi pred svetlobo in uporabiti v 3 urah.
After reconstitution, PhotoBarr solution should be protected from light and used immediately (within 3 hours).
Po pripravi je treba raztopino PhotoBarra zaščititi pred svetlobo in uporabiti v 3 urah.
After reconstitution, PhotoBarr solution should be protected from light and used immediately (within 3 hours).